se ha leído el artículo
array:24 [ "pii" => "S1578219018303524" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "copyrightAnyo" => "2018" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "formatos" => array:2 [ "EPUB" => 1 "HTML" => 1 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731018303983" "issn" => "00017310" "doi" => "10.1016/j.ad.2018.08.002" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2051" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:766" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 311 "formatos" => array:2 [ "HTML" => 170 "PDF" => 141 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Comentario Editorial</span>" "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219018303524" "doi" => "10.1016/j.adengl.2018.10.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303983?idApp=UINPBA000044" "url" => "/00017310/0000010900000009/v1_201811020614/S0001731018303983/v1_201811020614/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219018303196" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.05.032" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2004" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:767-70" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1 "HTML" => 1 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Opinion Article</span>" "titulo" => "What We Know About the Clinical Course of Nonsegmental Vitiligo: Experience of a Researcher and a Dermatologist" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "767" "paginaFinal" => "770" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Experiencia de un investigador y un dermatólogo sobre el conocimiento del curso clínico del vitiligo no segmentario" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M.L. Peralta-Pedrero, F. Jurado Santa-Cruz" "autores" => array:2 [ 0 => array:2 [ "nombre" => "M.L." "apellidos" => "Peralta-Pedrero" ] 1 => array:2 [ "nombre" => "F." "apellidos" => "Jurado Santa-Cruz" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018302898" "doi" => "10.1016/j.ad.2018.05.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018302898?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303196?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303196/v1_201811020640/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219018303172" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.06.024" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2019" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "cor" "cita" => "Actas Dermosifiliogr. 2018;109:765-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2 "HTML" => 2 ] "en" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "Local Experience with Vismodegib" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "765" "paginaFinal" => "766" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vismodegib, una experiencia local" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Pasquali" "autores" => array:1 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Pasquali" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303363" "doi" => "10.1016/j.ad.2018.06.008" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303363?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303172?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303172/v1_201811020640/en/main.assets" ] "asociados" => array:1 [ 0 => array:19 [ "pii" => "S1578219018303238" "issn" => "15782190" "doi" => "10.1016/j.adengl.2018.09.011" "estado" => "S300" "fechaPublicacion" => "2018-11-01" "aid" => "2040" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "pgl" "cita" => "Actas Dermosifiliogr. 2018;109:771-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 11 "formatos" => array:2 [ "HTML" => 7 "PDF" => 4 ] ] "en" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Consensus Document</span>" "titulo" => "Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "es" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "771" "paginaFinal" => "776" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea" ] ] "contieneResumen" => array:2 [ "en" => true "es" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1819 "Ancho" => 3083 "Tamanyo" => 264119 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">Algorithm for the treatment of chronic spontaneous urticaria with omalizumab. Abbreviations: UAS7, weekly Urticaria Activity Score; UCT, Urticaria Control Test.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Spertino, L. Curto Barredo, E. Rozas Muñoz, I. Figueras Nart, E. Serra Baldrich, M. Bonfill-Ortí, V. Expósito-Serrano, A. Guilabert, G. Melé Ninot, M. Villar Buil, J. Garcias Ladaria, X. García Navarro, M. Vilavella, I. Bielsa Marsol, G. Aparicio Ortiz, C. Baliu Piqué, A. Álvarez Abella, N. Lamas Domenech, J.M. Mascaró, S. Gómez, J.I. Torné Gutiérrez, A. Vicente Villa, A. Gimenez Arnau" "autores" => array:23 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Spertino" ] 1 => array:2 [ "nombre" => "L." "apellidos" => "Curto Barredo" ] 2 => array:2 [ "nombre" => "E." "apellidos" => "Rozas Muñoz" ] 3 => array:2 [ "nombre" => "I." "apellidos" => "Figueras Nart" ] 4 => array:2 [ "nombre" => "E." "apellidos" => "Serra Baldrich" ] 5 => array:2 [ "nombre" => "M." "apellidos" => "Bonfill-Ortí" ] 6 => array:2 [ "nombre" => "V." "apellidos" => "Expósito-Serrano" ] 7 => array:2 [ "nombre" => "A." "apellidos" => "Guilabert" ] 8 => array:2 [ "nombre" => "G." "apellidos" => "Melé Ninot" ] 9 => array:2 [ "nombre" => "M." "apellidos" => "Villar Buil" ] 10 => array:2 [ "nombre" => "J." "apellidos" => "Garcias Ladaria" ] 11 => array:2 [ "nombre" => "X." "apellidos" => "García Navarro" ] 12 => array:2 [ "nombre" => "M." "apellidos" => "Vilavella" ] 13 => array:2 [ "nombre" => "I." "apellidos" => "Bielsa Marsol" ] 14 => array:2 [ "nombre" => "G." "apellidos" => "Aparicio Ortiz" ] 15 => array:2 [ "nombre" => "C." "apellidos" => "Baliu Piqué" ] 16 => array:2 [ "nombre" => "A." "apellidos" => "Álvarez Abella" ] 17 => array:2 [ "nombre" => "N." "apellidos" => "Lamas Domenech" ] 18 => array:2 [ "nombre" => "J.M." "apellidos" => "Mascaró" ] 19 => array:2 [ "nombre" => "S." "apellidos" => "Gómez" ] 20 => array:2 [ "nombre" => "J.I." "apellidos" => "Torné Gutiérrez" ] 21 => array:2 [ "nombre" => "A." "apellidos" => "Vicente Villa" ] 22 => array:2 [ "nombre" => "A." "apellidos" => "Gimenez Arnau" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731018303594" "doi" => "10.1016/j.ad.2018.07.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731018303594?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303238?idApp=UINPBA000044" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303238/v1_201811020640/en/main.assets" ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Commentaries</span>" "titulo" => "An Algorithm to Guide the Rational, Evidence-Based Use of Omalizumab in the Treatment of Chronic Urticaria" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "766" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "R. Ruiz-Villaverde" "autores" => array:1 [ 0 => array:3 [ "nombre" => "R." "apellidos" => "Ruiz-Villaverde" "email" => array:1 [ 0 => "ismenios@hotmail.com" ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Unidad de Dermatología, Hospital Universitario San Cecilio, Granada, Spain" "identificador" => "aff0005" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Omalizumab is a monoclonal anti-IgE antibody currently used in the treatment of chronic spontaneous urticaria (CSU) as a third-line option in cases refractory to treatment with the licensed dose of the first-line treatment or up to 4 times that dose. The introduction of omalizumab into the therapeutic arsenal for CSU brought about a real revolution in the management of this condition. However, the dose recommended in the Summary of Product Characteristics—based on the results of pivotal studies carried out as part of the approval process—is 300 mg/mo for a period of up to 6 months. In the present issue, the Catalan-Balearic working group presents a treatment algorithm to guide the use of omalizumab in the management of CSU. They discuss the various aspects of management related to the rational and evidence-based use of this drug, including candidate population, monitoring tools (Urticaria Activity Score 7 [UAS7] and Urticarial Control Test [UCT]), starting dose and dose adjustment as well as the definition of response and response time.<a class="elsevierStyleCrossRef" href="#bib0015"><span class="elsevierStyleSup">1</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">In a novel approach, the authors of the algorithm propose the use of an increased dose of 450 or 600 mg every 4 weeks if the licensed doses do not achieve adequate control of disease activity—defined as a UAS7 of 6 or less. A study by the Catalan workgroup showed that 21% of patients require the increased dose to achieve a UAS7 of 6 or less and that 7% did not achieve disease control even with the higher dose. The predictors of partial response to 300 mg and the need for higher doses included prior treatment with ciclosporin, obesity, and age under 57 years.<a class="elsevierStyleCrossRef" href="#bib0020"><span class="elsevierStyleSup">2</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">This algorithm is of particular interest to dermatologists working in clinical practice.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Ruiz-Villaverde R. Aproximación a un uso racional y reglado de omalizumab en la urticaria crónica. Actas Dermosifiliogr. 2018;109:766.</p>" ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:2 [ 0 => array:3 [ "identificador" => "bib0015" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Algoritmo de tratamiento con omalizumab en urticaria crónica espontánea. Documento de consenso de la “Xarxa d’Urticària Catalana i Balear”" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J. Spertino" 1 => "E. Rozas Muñoz" 2 => "L. Curto Barredo" 3 => "I. Figueras Nart" 4 => "A. Gimenez Arnau" 5 => "E. Serra Baldrich" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.ad.2018.07.005" "Revista" => array:3 [ "tituloSerie" => "Actas Dermosifiliogr" "fecha" => "2018" "volumen" => "109" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0020" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Omalizumab updosing allows disease activity control in refractory patients with chronic spontaneous urticaria" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Curto-Barredo" 1 => "J. Spertino" 2 => "I. Figueras-Nart" 3 => "V. Expósito-Serrano" 4 => "A. Guilabert" 5 => "G. Melé-Ninot" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/bjd.16379" "Revista" => array:6 [ "tituloSerie" => "Br J Dermatol" "fecha" => "2018" "volumen" => "179" "paginaInicial" => "210" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/29368377" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.assets" "Apartado" => array:4 [ "identificador" => "66476" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Commentaries" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000009/v1_201811020640/S1578219018303524/v1_201811020640/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219018303524?idApp=UINPBA000044" ]
año/Mes | Html | Total | |
---|---|---|---|
2024 Noviembre | 6 | 8 | 14 |
2024 Octubre | 71 | 47 | 118 |
2024 Septiembre | 70 | 27 | 97 |
2024 Agosto | 81 | 53 | 134 |
2024 Julio | 58 | 30 | 88 |
2024 Junio | 69 | 22 | 91 |
2024 Mayo | 78 | 31 | 109 |
2024 Abril | 68 | 19 | 87 |
2024 Marzo | 63 | 25 | 88 |
2024 Febrero | 48 | 28 | 76 |
2024 Enero | 48 | 31 | 79 |
2023 Diciembre | 46 | 13 | 59 |
2023 Noviembre | 84 | 25 | 109 |
2023 Octubre | 45 | 22 | 67 |
2023 Septiembre | 35 | 31 | 66 |
2023 Agosto | 33 | 9 | 42 |
2023 Julio | 44 | 29 | 73 |
2023 Junio | 38 | 26 | 64 |
2023 Mayo | 38 | 33 | 71 |
2023 Abril | 28 | 22 | 50 |
2023 Marzo | 39 | 27 | 66 |
2023 Febrero | 34 | 21 | 55 |
2023 Enero | 37 | 23 | 60 |
2022 Diciembre | 42 | 45 | 87 |
2022 Noviembre | 20 | 23 | 43 |
2022 Octubre | 26 | 18 | 44 |
2022 Septiembre | 23 | 33 | 56 |
2022 Agosto | 21 | 28 | 49 |
2022 Julio | 32 | 37 | 69 |
2022 Junio | 26 | 28 | 54 |
2022 Mayo | 29 | 44 | 73 |
2022 Abril | 32 | 29 | 61 |
2022 Marzo | 37 | 42 | 79 |
2022 Febrero | 24 | 22 | 46 |
2022 Enero | 31 | 33 | 64 |
2021 Diciembre | 41 | 37 | 78 |
2021 Noviembre | 39 | 47 | 86 |
2021 Octubre | 43 | 70 | 113 |
2021 Septiembre | 35 | 42 | 77 |
2021 Agosto | 39 | 42 | 81 |
2021 Julio | 32 | 45 | 77 |
2021 Junio | 30 | 39 | 69 |
2021 Mayo | 42 | 53 | 95 |
2021 Abril | 97 | 72 | 169 |
2021 Marzo | 70 | 45 | 115 |
2021 Febrero | 55 | 43 | 98 |
2021 Enero | 49 | 51 | 100 |
2020 Diciembre | 36 | 42 | 78 |
2020 Noviembre | 41 | 38 | 79 |
2020 Octubre | 24 | 24 | 48 |
2020 Septiembre | 39 | 22 | 61 |
2020 Agosto | 26 | 26 | 52 |
2020 Julio | 19 | 24 | 43 |
2020 Junio | 32 | 28 | 60 |
2020 Mayo | 18 | 16 | 34 |
2020 Abril | 22 | 12 | 34 |
2020 Marzo | 20 | 9 | 29 |
2020 Febrero | 1 | 0 | 1 |
2019 Mayo | 1 | 0 | 1 |